Currently, treatment with insulin in T2DM is reserved for those patients with severe symptoms, a high likelihood of T1DM, low pancreatic beta-cell mass, or in whom control objectives have not been achieved with other treatments. This evidence concerns the gene INS and type 2 diabetes mellitus.